• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    2/13/26 4:08:56 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Arcutis Biotherapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    03969K108

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03969K108


    1Names of Reporting Persons

    Rubric Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,271,577.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,271,577.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,271,577.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.75 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    03969K108


    1Names of Reporting Persons

    David Rosen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,271,577.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,271,577.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,271,577.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.75 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arcutis Biotherapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    3027 Townsgate Road, Suite 300, Westlake Village, CA 91361
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock, $0.0001 par value (the "Common Stock") of Arcutis Biotherapeutics, Inc., a Delaware corporation (the "Issuer") reported herein; and (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.
    (c)Citizenship:

    Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    03969K108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a) - (c) is set forth in Rows 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons and in Item 4(b) is based on the 122,492,192 shares of Common Stock outstanding as of October 22, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission on October 28, 2025.
    (b)Percent of class:

    6.75  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rubric Capital Management LP
     
    Signature:/s/ Michael Nachmani
    Name/Title:Michael Nachmani / Chief Operating Officer
    Date:02/13/2026
     
    David Rosen
     
    Signature:/s/ David Rosen
    Name/Title:David Rosen / Individually
    Date:02/13/2026
    Get the next $ARQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    7/25/2025$18.00Neutral
    Goldman
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    More analyst ratings

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

    WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3

    3/18/26 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

    ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained disease control for a median duration of ~8 monthsThese results further support the Company's focus on expanding options for pediatric populations WESTLAKE VILLAGE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Pediatric Dermatology published data from the Phase 3 open-label

    3/10/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

    WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company's legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE® (roflumilast) portfolio, and protection of the Company's intellectual property, as well as any corporate transactions. "I am

    3/5/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/6/25 8:44:37 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    5/23/25 4:04:50 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    SEC Filings

    View All

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 6:21:36 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:59:41 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:25:46 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leonard Keith R sold $997,195 worth of shares (39,272 units at $25.39) and exercised 39,272 shares at a strike of $8.28 (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/4/26 4:17:39 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Welgus Howard G. sold $256,518 worth of shares (10,000 units at $25.65), decreasing direct ownership by 17% to 49,744 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/4/26 4:16:29 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Edwards Larry Todd was granted 30,000 shares and sold $92,846 worth of shares (3,687 units at $25.18), increasing direct ownership by 18% to 175,178 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    3/3/26 8:43:03 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

    12/30/24 7:23:09 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

    Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

    8/28/24 7:20:44 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

    Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:3

    1/22/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

      Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October Company provides initial 2026 full year net product sales guidance of $455–$470 million WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported

    10/28/25 8:30:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

    Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

    9/27/23 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/13/24 4:30:25 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/6/24 4:00:53 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care